Grinshpun, A., Sonnenblick, A., Leshem, Y., Khutsurauli, S., Fridman, N., Remilah, A. A., Breuer, S., Rosengarten, O. S., Katz, D. (2026). A phase II study evaluating treatment discontinuation of dual anti-HER2 therapy in metastatic HER2-positive breast cancer after five years of sustained complete response (FREEDOME-trial).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1143